Human-Induced Pluripotent Stem Cell‒Derived Keratinocytes, as Therapeutic Option in Vitiligo
- PMID: 38189899
- DOI: 10.1007/7651_2023_510
Human-Induced Pluripotent Stem Cell‒Derived Keratinocytes, as Therapeutic Option in Vitiligo
Abstract
Vitiligo is a skin condition affecting 1% of the global population, causing non-scaly, chalky-white macules on the skin and hair. It is caused by the pathologic destruction of melanocytes, which produce melanin. Research has focused on the abnormalities of melanocytes and their interaction with neighboring keratinocytes. Current treatments are mainly immunosuppressive drugs and UV radiation, which are scarce and ineffective. To treat vitiligo, regenerative medicine techniques, such as cell-based and cell-free methods, are recommended. Keratinocyte cell transplantation has shown promising results in treating vitiligo. Moreover, studies suggest individualized therapy for diseases can be provided by reprogramming somatic cells into induced pluripotent stem cells. On the other hand, differentiation into particular cell types is a key component of induced pluripotent stem cells-based treatment. In this chapter, the differentiation and validation of human induced pluripotent stem cells into a keratinocyte as a therapeutic option in vitiligo will be discussed.
Keywords: Cell therapy; Differentiation; Induced pluripotent stem cells; Keratinocyte; Regenerative medicine; Vitiligo.
© 2024. Springer Science+Business Media, LLC.
Similar articles
-
The regenerative potential of autologous stem and somatic cells in vitiligo.Eur J Dermatol. 2024 Feb 1;34(1):13-17. doi: 10.1684/ejd.2024.4602. Eur J Dermatol. 2024. PMID: 38557453 Review.
-
Development of melanocye-keratinocyte co-culture model for controls and vitiligo to assess regulators of pigmentation and melanocytes.Indian J Dermatol Venereol Leprol. 2012 Sep-Oct;78(5):599-604. doi: 10.4103/0378-6323.100567. Indian J Dermatol Venereol Leprol. 2012. PMID: 22960816
-
Keratinocytes suppress TRP-1 expression and reduce cell number of co-cultured melanocytes - implications for grafting of patients with vitiligo.Pigment Cell Res. 2001 Apr;14(2):116-25. doi: 10.1034/j.1600-0749.2001.140207.x. Pigment Cell Res. 2001. PMID: 11310791 Clinical Trial.
-
Comparative study of human-induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and skin fibroblasts.Eur Heart J. 2013 Sep;34(33):2618-29. doi: 10.1093/eurheartj/ehs203. Epub 2012 Jul 12. Eur Heart J. 2013. PMID: 22798560
-
Trends in Regenerative Medicine: Repigmentation in Vitiligo Through Melanocyte Stem Cell Mobilization.Med Res Rev. 2017 Jul;37(4):907-935. doi: 10.1002/med.21426. Epub 2016 Dec 28. Med Res Rev. 2017. PMID: 28029168 Free PMC article. Review.
Cited by
-
Understanding the Impact of Ostomy Dejecta Constituents on Peristomal Skin Health and Models for Its Characterisation.Int Wound J. 2025 Jun;22(6):e70514. doi: 10.1111/iwj.70514. Int Wound J. 2025. PMID: 40400213 Free PMC article. Review.
References
-
- Aghayan HR, Goodarzi P, Arjmand B (2015) GMP-compliant human adipose tissue-derived mesenchymal stem cells for cellular therapy. Methods Mol Biol 1283:93–107. https://doi.org/10.1007/7651_2014_112 - DOI - PubMed
-
- Aghayan HR, Payab M, Mohamadi-Jahani F et al (2021) GMP-compliant production of human placenta-derived mesenchymal stem cells. Methods Mol Biol 2286:213–225. https://doi.org/10.1007/7651_2020_282 - DOI - PubMed
-
- Aghayan HR, Hosseini MS, Gholami M et al (2022) Mesenchymal stem cells’ seeded amniotic membrane as a tissue-engineered dressing for wound healing. Drug Deliv Transl Res:1–12
-
- Ali G, Abdelalim EM (2022) Directed differentiation of human pluripotent stem cells into epidermal keratinocyte-like cells. STAR Protoc 3(3):101613. https://doi.org/10.1016/j.xpro.2022.101613 - DOI - PubMed - PMC
-
- Allam M, Riad H (2013) (2013) Concise review of recent studies in vitiligo. Qatar Med J 2:1–19. https://doi.org/10.5339/qmj.2013.10 - DOI
MeSH terms
LinkOut - more resources
Full Text Sources
Medical